[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 4109 Reported in Senate (RS)]
<DOC>
Calendar No. 443
119th CONGRESS
2d Session
S. 4109
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and
for other purposes.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
March 17, 2026
Mr. Reed (for himself, Mr. Scott of South Carolina, Ms. Smith, and Mr.
Lankford) introduced the following bill; which was read twice and
referred to the Committee on Health, Education, Labor, and Pensions
June 22, 2026
Reported by Mr. Cassidy, with an amendment
[Strike out all after the enacting clause and insert the part printed
in italic]
_______________________________________________________________________
A BILL
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and
for other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
<DELETED>SECTION 1. SHORT TITLE.</DELETED>
<DELETED> This Act may be cited as the ``Stem Cell Therapeutic and
Research Reauthorization Act of 2026''.</DELETED>
<DELETED>SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL
TRANSPLANTATION PROGRAM.</DELETED>
<DELETED> Section 379B of the Public Health Service Act (42 U.S.C.
274m) is amended--</DELETED>
<DELETED> (1) by striking ``appropriated $31,009,000'' and
inserting the following: ``appropriated--</DELETED>
<DELETED> ``(1) $31,009,000'';</DELETED>
<DELETED> (2) in paragraph (1), as so inserted, by striking
the period at the end and inserting ``; and''; and</DELETED>
<DELETED> (3) by adding at the end the following:</DELETED>
<DELETED> ``(2) $33,009,000 for each of fiscal years 2027
through 2031.''.</DELETED>
<DELETED>SEC. 3. CORD BLOOD INVENTORY.</DELETED>
<DELETED> Section 2(g) of the Stem Cell Therapeutic and Research Act
of 2005 (42 U.S.C. 274k note) is amended by striking ``2026'' and
inserting ``2031''.</DELETED>
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Stem Cell Therapeutic and Research
Reauthorization Act of 2026''.
SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL TRANSPLANTATION
PROGRAM.
Section 379B of the Public Health Service Act (42 U.S.C. 274m) is
amended--
(1) by striking ``appropriated $31,009,000'' and inserting
the following: ``appropriated--
``(1) $31,009,000'';
(2) in paragraph (1), as so inserted, by striking the
period at the end and inserting ``; and''; and
(3) by adding at the end the following:
``(2) $33,009,000 for each of fiscal years 2027 through
2031.''.
SEC. 3. CORD BLOOD INVENTORY.
Section 2 of the Stem Cell Therapeutic and Research Act of 2005 (42
U.S.C. 274k note) is amended--
(1) in subsection (a), by striking ``the inventory goal of
at least 150,000 new units of high-quality cord blood'' and
inserting ``a sufficient supply, as determined by the
Secretary, of high-quality cord blood units'';
(2) in subsection (c)--
(A) in paragraph (2), by striking ``in perpetuity
or''; and
(B) by amending paragraph (5) to read as follows:
``(5) agree to the terms described in subsection (e).'';
(3) in subsection (d)--
(A) in paragraph (1), by striking ``paragraph (2)''
and inserting ``paragraphs (2) and (4)''; and
(B) in paragraph (4)--
(i) in the heading, by striking ``science''
and inserting ``available scientific and
clinical evidence''; and
(ii) by striking ``the best scientific
information available in order to maximize the
number of cord blood units available'' and
inserting ``current scientific and clinical
information in order to maximize the
availability of high-quality cord blood units
meeting applicable clinical and quality
standards'';
(4) by redesignating subsections (e) through (g) as
subsections (g) through (i), respectively;
(5) by inserting after subsection (d) the following:
``(e) Transfer of Units.--If the Secretary determines through an
assessment, or through petition by a qualified cord blood bank, that a
cord blood bank is no longer operational, does not meet clinical and
quality standards informed by current scientific and clinical
information, does not meet the requirements for an extension under
subsection (d), or does not meet the requirements of section 379(d)(4)
of the Public Health Service Act, and as a result may not distribute
the units, the Secretary may transfer the units collected by such cord
blood bank pursuant to this section to another qualified cord blood
bank or entity approved by the Secretary to ensure continued
availability of high-quality cord blood units.
``(f) Inventory Management.--
``(1) In general.--The Secretary, in consultation with the
Advisory Council on Blood Stem Cell Transplantation as
appropriate, shall manage the size and composition of the
National Cord Blood Inventory to maximize clinical utility,
ensure genetic diversity, and promote the efficient use of
Federal resources.
``(2) Considerations.--In carrying out paragraph (1), the
Secretary may--
``(A) on the initiative of the Secretary or upon
petition by a qualified cord blood bank, make
determinations regarding the continued storage of cord
blood units based on the best available scientific and
clinical evidence; and
``(B) prioritize the collection, retention, or
disposition of cord blood units based on scientific,
clinical, or operational considerations, as the
Secretary determines appropriate.'';
(6) in subsection (h), as so redesignated--
(A) by redesignating paragraphs (4) and (5) as
paragraphs (5) and (6), respectively; and
(B) by inserting after paragraph (3) the following:
``(4) The term `high-quality cord blood unit' means a unit
of cord blood that meets current industry standards and
requirements of the Food and Drug Administration.''; and
(7) in subsection (i), as so redesignated, by striking
``2022 through 2026'' and inserting ``2027 through 2031''.
SEC. 4. PERIODIC REVIEW OF STATE OF SCIENCE UNDER THE NATIONAL PROGRAM.
Section 379(o) of the Public Health Service Act (42 U.S.C. 274k(o))
is amended--
(1) in paragraph (1)--
(A) by striking ``Not less'' and inserting
``Beginning 1 year after the date of enactment of the
Stem Cell Therapeutic and Research Reauthorization Act
of 2026, not less''; and
(B) by striking ``and birthing tissues'' and
inserting ``, high-quality cord blood units (as defined
in section 2(h) of the Stem Cell Therapeutic and
Research Act of 2005), and other emergent
technologies''; and
(2) in paragraph (2), by striking ``June 30, 2025'' and
inserting ``3 years after the date of enactment of the Stem
Cell Therapeutic and Research Reauthorization Act of 2026''.
Calendar No. 443
119th CONGRESS
2d Session
S. 4109
_______________________________________________________________________
A BILL
To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and
for other purposes.
_______________________________________________________________________
June 22, 2026
Reported with an amendment